**R&I FY 2025 $8.9bn, +12%**
Breztri +13%, fastest growing medicine in Tezspire +66%, further share gains in asthma, Farxiga +2%, strength in Europe and EM ex-China, V&l (33%), Beyfortus sustained demand growth, Collaboration partners: Amgen (Tezspire); Sanofi (Beyfortus);